These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 411754)

  • 1. Glycolipoprotein from Pseudomonas aeruginosa as a protective antigen against P. aeruginosa infection in mice.
    Sensakovic JW; Bartell PF
    Infect Immun; 1977 Nov; 18(2):304-9. PubMed ID: 411754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Passive immunization against Pseudomonas with a ribosomal vaccine-induced immune serum and immunoglobulin fractions.
    Lieberman MM; McKissock DC; Wright GL
    Infect Immun; 1979 Feb; 23(2):509-21. PubMed ID: 106013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective properties and haemagglutinins in serum from humans and in serum from mice injected with a new polyvalent Pseudomonas vaccine.
    Jones RJ; Roe EA
    Br J Exp Pathol; 1975 Feb; 56(1):34-43. PubMed ID: 812544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serologic and protective cross-reactivity of antisera to Pseudomonas aeruginosa extracellular slime glycolipoprotein.
    Yushkova NA; Kholodkova EV; Korobova TS; Stanislavsky ES
    Acta Microbiol Hung; 1986; 33(2):147-56. PubMed ID: 3101393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polysaccharide of the slime glycolipoprotein of Pseudomonas aeruginosa.
    Koepp LH; Orr T; Bartell PF
    Infect Immun; 1981 Sep; 33(3):788-94. PubMed ID: 6793519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A polyvalent human gamma-globulin immune to Pseudomonas aeruginosa: passive protection of mice against lethal infection.
    Fisher MW
    J Infect Dis; 1977 Aug; 136 Suppl():S181-5. PubMed ID: 70492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylactic and therapeutic efficacy of immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharide against murine experimental corneal infection.
    Preston MJ; Gerçeker AA; Koles NL; Pollack M; Pier GB
    Invest Ophthalmol Vis Sci; 1997 Jun; 38(7):1418-25. PubMed ID: 9191605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective immunity induced in mice by immunization with high-molecular-weight polysaccharide from Pseudomonas aeruginosa.
    Pier GB; Sidberry HF; Sadoff JC
    Infect Immun; 1978 Dec; 22(3):919-25. PubMed ID: 103841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of nonagglutinating antibody in the protracted immunity of vaccinated mice to Pseudomonas aeruginosa infection.
    Moody MR; Kessel RW; Young VM; Fiset P
    Infect Immun; 1978 Sep; 21(3):905-13. PubMed ID: 101467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of anti-slime glycolipoprotein serum on the interaction between Pseudomonas aeruginosa and macrophages.
    Bartell PF; Krikszens A
    Infect Immun; 1980 Mar; 27(3):777-83. PubMed ID: 6769808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Passive protective properties of serum fractions from mice inoculated with an anti-pseudomonas vaccine.
    Jones RJ; Hall M; Ricketts CR
    Immunology; 1972 Dec; 23(6):889-95. PubMed ID: 4630781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specificity of the protective response induced by the slime layer of Pseudomonas aeruginosa.
    Mates A; Zand P
    J Hyg (Lond); 1974 Aug; 73(1):75-84. PubMed ID: 4213979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum antibody and ocular responses to murine corneal infection caused by Pseudomonas aeruginosa.
    Berk RS; Montgomery IN; Hazlett LD
    Infect Immun; 1988 Dec; 56(12):3076-80. PubMed ID: 3141279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pseudomonas aeruginosa infection and vaccination in the rat.
    Kostiala AA
    J Med Microbiol; 1980 May; 13(2):201-12. PubMed ID: 6770090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection.
    Zaidi TS; Priebe GP; Pier GB
    Infect Immun; 2006 Feb; 74(2):975-83. PubMed ID: 16428743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Experimental study of the dynamics of the formation of protective antibodies to the antigens of the slime of Pseudomonas aeruginosa].
    Iushkova NA; Stanislavskiĭ ES; Landsman NM
    Zh Mikrobiol Epidemiol Immunobiol; 1983 Mar; (3):78-83. PubMed ID: 6405564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new polyvalent pseudomonas vaccine.
    Merle P; Robbel L; Hungerer KD
    Behring Inst Mitt; 1984 Nov; (76):113-20. PubMed ID: 6441560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunization of burn-patients with a Pseudomonas aeruginosa outer membrane protein vaccine elicits antibodies with protective efficacy.
    Lee NG; Jung SB; Ahn BY; Kim YH; Kim JJ; Kim DK; Kim IS; Yoon SM; Nam SW; Kim HS; Park WJ
    Vaccine; 2000 Mar; 18(18):1952-61. PubMed ID: 10699346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prophylactic effects of human IgG derived from sera containing high anti-PcrV titers against pneumonia-causing Pseudomonas aeruginosa.
    Kinoshita M; Kato H; Yasumoto H; Shimizu M; Hamaoka S; Naito Y; Akiyama K; Moriyama K; Sawa T
    Hum Vaccin Immunother; 2016 Nov; 12(11):2833-2846. PubMed ID: 27454613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protection against Pseudomonas aeruginosa infection by immunisation with fractions of culture filtrates of Ps. aeruginosa.
    Jones RJ
    Br J Exp Pathol; 1968 Oct; 49(5):411-20. PubMed ID: 4973304
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.